# Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer

Source: https://onco.cc/trials/nct01872260/  
OnCo record `nct01872260` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of LEE011 in advanced solid tumours, run by Novartis Pharmaceuticals, active and no longer recruiting.

## Summary

Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer is a phase 1/2 interventional study registered as NCT01872260 by Novartis Pharmaceuticals, with 255 participants enrolled, started 2013-10-22 and due to reach its primary completion in 2027-02-26. Interventions recorded: LEE011, Letrozole and BYL719.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT01872260
- Phase: 1/2
- Setting: A Phase Ib/II, Multicenter Study of the Combination of LEE011 and BYL719 With Letrozole in Adult Patients With Advanced ER+ Breast Cancer
- Sponsor: Novartis Pharmaceuticals
- Enrolled: 255

## Sources

- ClinicalTrials.gov NCT01872260: https://clinicaltrials.gov/study/NCT01872260

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Advanced Accelerator Applications (Novartis)](https://onco.cc/companies/advanced-accelerator-applications/)

---
JSON: https://onco.cc/api/v1/entities/nct01872260.json